Philips Dictation and Nuance expand their long-standing partnership with SpeechExec Enterprise 7.0 15/10/2020 — VIENNA — (BUSINESS WIRE) The new version of the Philips dictation workflow solution for enterprise businesses, […]
Merger adds significant scale, enhances its digitally-integrated solutions portfolio, and expands its European presence An elevated enterprise value of approximately US$3.8 billion positions TELUS International for a future initial public […]
Bartender from Vienna created the most avant-garde martini at this year’s competition, hosted in Bilbao ahead of The World’s 50 Best Restaurants 20/06/2018 — BILBAO, Spain — (BUSINESS WIRE) After […]
16/02/2018 — LINZ, Austria — (BUSINESS WIRE) On February 5, 2018, in Linz, SPI Group achieved yet another significant legal victory in its long-running dispute with Russian state-owned entity Federal […]
Samsung to join AUDI AG as a major investor in TTTech, which will develop new open-innovation platform for ADAS/AV systems; HARMAN to integrate this open platform offering to its innovative […]
European Facility Will Boost Global Vaccine Production Capacity 08/08/2017 — MADISON, N.J. — (BUSINESS WIRE) MSD Animal Health, known as Merck Animal Health in the United States and Canada, today […]
New LIFEPAK AED Response System Offers Connectivity, Intuitive Design and Unique Technology to Analyse Heart Rhythm during CPR New AED Solution to be Exhibited at MEDICA 2016, November 14-17 02/11/2016 […]
20/10/2016 — VIENNA, Austria & SOFIA, Bulgaria — (BUSINESS WIRE) UniCredit Bank Austria AG and UniCredit Bulbank AD increased and amended its current senior facility with Business Park Sofia (BPS), […]
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to MSD’s growing body of clinical data for KEYTRUDA.
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) – a type of head and neck cancer – whose tumors express PD-L1 (≥1% of cells in tumor nests or PD-L1+ bands in stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu, National Taiwan University Hospital, at the European Cancer Congress (ECC) in Vienna (Abstract #2801).